Tumor growth in vivo, and in vitro assays measuring cell survival and apoptosis demonstrated resistance of COMP-expressing breast cancer cells against all studied types of anti-cancer drugs, which are used in clinics as a first or second line of therapy [23]. Here, COMP is linked to neoplasm.